Abstract
Viroporins are ion channels found in many viruses, where they contribute to virus life cycle and thereby pathogenesis. Viroporin targeting is a known, yet largely unexplored, therapeutic strategy so far only used in Influenza A with the drugs amantadine and rimantadine. In this review, we seek to utilize the inhibition by amantadine of the viroporin Protein E in SARS-CoV-2 in an attempt to treat COVID-19 in its early stages. We are executing a double-blinded placebo-controlled trial based on promising in vivo and in vitro work as a stepping-stone for establishing a therapeutic antiviral regime: blocking of viroporins.
Translated title of the contribution | The antiviral targeting potential of viroporins |
---|---|
Original language | Danish |
Article number | V02220103 |
Journal | Ugeskrift for Laeger |
Volume | 184 |
Issue number | 24 |
Number of pages | 8 |
ISSN | 0041-5782 |
Publication status | Published - 13 Jun 2022 |